logo
Plus   Neg
Share
Email

UCB Agrees To Buy Ra Pharma In $2.1 Bln Deal

UCB agreed to acquire Ra Pharmaceuticals Inc. (RARX) for $48 per share in cash, valuing the deal at about $2.1 billion, net of Ra Pharma cash.

The cash consideration represents an about 93% premium to Ra Pharma shareholders based on the 30-day volume weighted average closing stock price of Ra Pharma prior to signing.

The companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions.

It is expected to complete the transaction by the end of the first-quarter of 2020.

UCB said that the acquisition will not impact its 2019 financial guidance. It would be dilutive to UCB's mid-term earnings level.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
Follow RTT
>